State Street’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-2,797,916
| Closed | -$66.1M | – | 4427 |
|
|
2023
Q4 | $66.1M | Buy |
2,797,916
+511,972
| +22% | +$9.12M | ﹤0.01% | 1549 |
|
|
2023
Q3 | $34.1M | Sell |
2,285,944
-22,549
| -1% | -$299K | ﹤0.01% | 1842 |
|
|
2023
Q2 | $25.3M | Buy |
2,308,493
+1,639,457
| +245% | +$15.3M | ﹤0.01% | 2097 |
|
|
2023
Q1 | $5.83M | Buy |
669,036
+330,763
| +98% | +$2.65M | ﹤0.01% | 2934 |
|
|
2022
Q4 | $2.12M | Hold |
338,273
| – | – | ﹤0.01% | 3358 |
|
|
2022
Q3 | $1.18M | Sell |
338,273
-23,847
| -7% | -$85.7K | ﹤0.01% | 3564 |
|
|
2022
Q2 | $1.07M | Sell |
362,120
-995,930
| -73% | -$2.38M | ﹤0.01% | 3618 |
|
|
2022
Q1 | $4.22M | Buy |
1,358,050
+24,160
| +2% | +$76.1K | ﹤0.01% | 3268 |
|
|
2021
Q4 | $4.51M | Buy |
1,333,890
+56,923
| +4% | +$216K | ﹤0.01% | 3287 |
|
|
2021
Q3 | $4.66M | Sell |
1,276,967
-80,257
| -6% | -$316K | ﹤0.01% | 3274 |
|
|
2021
Q2 | $5.92M | Buy |
1,357,224
+66,378
| +5% | +$294K | ﹤0.01% | 3169 |
|
|
2021
Q1 | $5.86M | Sell |
1,290,846
-517,501
| -29% | -$2.79M | ﹤0.01% | 2978 |
|
|
2020
Q4 | $10.4M | Buy |
1,808,347
+167,833
| +10% | +$1.27M | ﹤0.01% | 2609 |
|
|
2020
Q3 | $11.9M | Buy |
1,640,514
+226,043
| +16% | +$1.21M | ﹤0.01% | 2351 |
|
|
2020
Q2 | $4.94M | Sell |
1,414,471
-7,095
| -0.5% | -$20.5K | ﹤0.01% | 2761 |
|
|
2020
Q1 | $2.1M | Buy |
1,421,566
+11,652
| +0.8% | +$19.6K | ﹤0.01% | 3049 |
|
|
2019
Q4 | $2.76M | Sell |
1,409,914
-171,539
| -11% | -$644K | ﹤0.01% | 3129 |
|
|
2019
Q3 | $8.1M | Sell |
1,581,453
-24,881
| -2% | -$151K | ﹤0.01% | 2571 |
|
|
2019
Q2 | $11.5M | Buy |
1,606,334
+341,579
| +27% | +$3.87M | ﹤0.01% | 2437 |
|
|
2019
Q1 | $16.8M | Sell |
1,264,755
-17,640
| -1% | -$188K | ﹤0.01% | 2156 |
|
|
2018
Q4 | $10.1M | Sell |
1,282,395
-32,835
| -2% | -$313K | ﹤0.01% | 2427 |
|
|
2018
Q3 | $14.6M | Sell |
1,315,230
-6,333
| -0.5% | -$78.7K | ﹤0.01% | 2384 |
|
|
2018
Q2 | $17.7M | Buy |
1,321,563
+1,087,773
| +465% | +$13.6M | ﹤0.01% | 2212 |
|
|
2018
Q1 | $3.04M | Buy |
233,790
+189,268
| +425% | +$2.35M | ﹤0.01% | 3003 |
|
|
2017
Q4 | $409K | Buy |
44,522
+9,822
| +28% | +$83.9K | ﹤0.01% | 3477 |
|
|
2017
Q3 | $279K | Buy |
+34,700
| New | +$235K | ﹤0.01% | 3564 |
|
Other funds holding CBAY
State Street's CBAY Position: Q1 2024 in Review
State Street sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 2,797,916 shares — an estimated $66.1M sold.
State Street first reported a position in CBAY in Q3 2017 and held it in 26 quarters. The position peaked at $66.1M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- State Street reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- State Street sold 2,797,916 Cymabay Therapeutics shares in Q1 2024, an estimated $66.1M.
- State Street first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 26 quarters.
- State Street's Cymabay Therapeutics position peaked at $66.1M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.